Rivaroxaban

Administration

• Type: Anticoagulant, Factor Xa Inhibitor
• Dosage Forms: 10, 15, 20
• Routes of Administration:
• Common Trade Names: Xarelto

Adult Dosing

• Thromboembolism/stroke prophylaxis: 20 mg PO qd
• DVT Prophylaxis: 10 mg PO qd x35 days; Start: 6-10h post-op once hemostasis established
• DVT/PE Prophylaxis, recurrent: 20 mg PO qd
• DVT/PE Treatment: 20 mg PO qd

Special Populations

• Pregnancy Risk Factor: C

Renal Dosing

• Thromboembolism/stroke prophylaxis
  • CrCl 15-50: 15 mg qd; CrCl <15: avoid use
• DVT prophylaxis
  • CrCl 30-50: caution advised; CrCl <30: avoid use
• DVT/PE prophylaxis, recurrent
  • CrCl <30: avoid use
• DVT/PE tx
  • CrCl <30: avoid use

Hepatic Dosing

• Avoid Use In:
  • Child-Pugh Class B or C
  • Coagulopathy-assoc. hepatic disease

Contraindications

• Active major bleeding
• Hepatic impairment, Child-Pugh Class B or C
• Coagulopathy-assoc. hepatic disease
• CrCl <30 (DVT prophylaxis, recurrent DVT/PE prophylaxis, DVT/PE tx use)
• CrCl <15 (thromboembolism/stroke prophylaxis use)
• Acute PE with hemodynamic instability
• Acute PE requiring thrombolysis or pulmonary embolectomy

Adverse Reactions

Serious

• Bleeding, severe
• Epidural/spinal hematoma
• Thrombocytopenia
• Agranulocytosis
• Hypersensitivity reaction
• Stevens-Johnson syndrome
• Hepatitis

Common

• Bleeding
• Back pain
• Pruritus
• Elevated ALT
• Thrombocytopenia

Pharmacology

• Half-life: 5-9 hours
• Metabolism: CYP450
• Excretion: 66% Urine, 28% Feces

Mechanism of Action

• Inhibits platelet activation and fibrin clot formation via direct, selective and reversible inhibition of factor Xa in both the intrinsic and extrinsic coagulation pathways

See Also

• Anticoagulant reversal for life-threatening bleeds

References

<UpToDate, Epocrates>